The DREAMING clinical trial is part of the DREAMING project, which has the objective to demonstrate that the DREAMING platform consisting of integrated health monitoring, alarm handling and videoconferencing services produces clinical benefits to its users and economic benefits to the health authorities. The study evaluates the long-term (30 months) effect of continuous use of the DREAMING subsystems and is testing the hypothesis that such use is superior to usual care alone in reducing the deterioration of health related quality of life that is associated to age and chronic disease. It also tests the hypothesis that the DREAMING environment is superior to usual care in delaying the transfer to nursing or elderly homes and in reducing the incidence and duration of hospitalisation episodes. The trial will also evaluate the cost-effectiveness of the DREAMING platform. Outcomes are assessed in six different health care systems (Denmark, Estonia, Germany, Italy, Spain and Sweden) and will represent a basis for the adoption of DREAMING services by the respective health authorities.
Homes of participants are equipped with environmental sensors, motion detection, and with wireless sensors for blood pressure, blood glucose, body weight, blood oxygen saturation, peak expiratory flow and electrocardiogram. Disease related parameters are monitored at least daily and the measured values are transmitted to a central monitoring unit. In case of abnormal values, health alarms are generated and transmitted to the local health authorities to trigger eventual intervention by the physicians and nurses who normally follow the participants. Participants and health professionals can stay in contact via an easy to use, home television based videoconferencing system. Participants are also equipped with a a personal alarm and GPS-enhanced localisation system.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
300
Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
Langeland Municipality
Langeland, Denmark
East Tallin Central Hospital
Tallinn, Estonia
Pflegwerk Berlin, Mediplus
Berlin, Germany
Azienda per i Servizi Sanitari ASS N.1
Trieste, Italy
Servicio Aragones de Salud
Barbastro, Spain
GP Surgery
Heby, Sweden
Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period
Time frame: 0, 15, 30 months
Time to permanent transfer to elderly homes
Time frame: Measured at month 30
Total and average length of stay in hospital
Time frame: Measured at month 30
Number of consultations with general practitioners
Time frame: Measured at month 30
Number of consultations with medical specialists
Time frame: Measured at month 30
Number of home visits by nurses
Time frame: Measured at month 30
Number of ambulance transports
Time frame: Measured at month 30
Number of accesses to emergency rooms
Time frame: Measured at month 30
Number of falls
Time frame: Measured at month 30
Number of femur fractures
Time frame: Measured at month 30
HbA1c change over time (only for participants with a diagnosis of diabetes)
Time frame: Measured at month 30
Survival
Time frame: Measured at month 30
Depression as measured by HADS
Time frame: Measured at months 0, 15 and 30
Number of hospitalisations
Time frame: Measured at month 30
Number of permanent transfers to elderly homes
Time frame: Measured at month 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.